Simoa® Immunoassays Enable Ultrasensitive Detection of Blood-Based Biomarkers for Parkinson's Disease

Publication Brief


Parkinson’s disease (PD) is a progressive and debilitating neurodegenerative disorder that affects millions of people worldwide. Therapeutic management can ease symptoms and slow progression, especially if implemented in the early stages of the disease. However, traditional diagnostic methods are limited to detecting motor deficits, which may not manifest until the later stages of the disease progression. This leaves a critical gap in identifying asymptomatic patients who could benefit most from early therapeutic intervention. Download our flyer to learn more and to view a sampling of peer-reviewed studies employing Simoa® technology for Parkinson's disease research.